drugset / Trial / NCT07429045
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this trial is to evaluate the pharmacokinetics of a single subcutaneous (SC) dose of AMG 133 in participants with various degrees of renal impairment compared to participants with normal renal function.
Timeline
- Start
- 2025-03-11
- Primary completion
- 2025-11-21
- Completion
- 2025-11-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maridebart Cafraglutide | Unknown | — | Subcutaneous |